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BACKGROUND. Cutaneous lymphomas expressing a cytotoxic or natural killer (NK)
cell phenotype represent a group of lymphoproliferative disorders for which there
is currently much confusion and little consensus regarding the best nomenclature
and classification.
METHODS. This study analyzes 48 cases of primary cutaneous lymphoma express-
ing cytotoxic proteins and/or the NK cell marker, CD56. These cases were collected
for a workshop of the European Organization for Research and Treatment of
Cancer Cutaneous Lymphoma Task Force, to better clarify the clinical, morpho-
logic, and phenotypic features of these uncommon tumors.
RESULTS. Several categories with different clinical and pathologic features were
delineated: 1) aggressive, CD8, epidermotropic, cytotoxic T-cell lymphoma; 2)
mycosis fungoides, cytotoxic immunophenotype variant; 3) subcutaneous pannic-
ulitis-like T-cell lymphoma; 4) NK/T-cell lymphoma, nasal type; 5) CD4, NK cell
lymphoma; 6) blastoid NK cell lymphoma; (7) intravascular NK-like lymphoma;
and 8) cytotoxic, peripheral T-cell lymphoma.
CONCLUSIONS. Our data show that primary cutaneous cytotoxic/NK cell lympho-
mas include distinct groups of diseases, clinically, histologically, and biologically.
Because the finding of a cytotoxic phenotype often has prognostic significance, the
routine use of cytotoxic markers in the diagnosis and classification of cutaneous
lymphomas should be expanded. Cancer 2003;97:610 –27.
© 2003 American Cancer Society.
DOI 10.1002/cncr.11107
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nosis, therapy.
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Several subtypes of cutaneous lymphomas (al-though reported in the current literature and re-
cently included in the World Health Organization
[WHO] classification1) are not yet mentioned, or are
included as provisional entities, in the Cutaneous
Lymphoma Study Group of the European Organiza-
tion for Research and Treatment of Cancer (EORTC)
classification.2 This is the result of the absence of a
distinctive clinicopathologic presentation. Among the
categories of this “gray” area, cutaneous lymphomas
expressing a cytotoxic or natural killer (NK) cell phe-
notype represent a group of lymphoproliferative dis-
orders for which there is currently much confusion
and little consensus regarding the best nomenclature
and classification. In particular, the rarity of tumors
expressing the NK cell phenotype, especially in West-
ern countries, represents a major limitation to a com-
plete understanding. The recognition of lymphoid
neoplasms expressing a cytotoxic or an NK-like phe-
notype may have relevant clinical and therapeutic im-
plications because it has been reported that many of
them follow an aggressive clinical course.3– 6
The aim of this report is to describe the spectrum
of primary cutaneous lymphomas expressing cyto-
toxic proteins and/or the NK cell marker, CD56, and to
better clarify their clinical, morphologic, and pheno-
typic features.
MATERIALS AND METHODS
A workshop of the EORTC Cutaneous Lymphoma Task
Force was held on July 3–5, 1998, at the Study Center
“I Cappuccini,” S. Miniato (Pisa, Italy). Cases were
solicited on the following topics: 1) lymphomas in
which tumor cells expressed at least one of the follow-
ing molecules, namely, CD8, TIA-1, or CD56; 2) lym-
phoma showing features of subcutaneous or angio-
centric lymphoma; and 3) lymphoma expressing the
/ phenotype. Sixty examples of primary cutaneous
lymphoma exhibiting one the aforementioned fea-
tures were provided.
During the workshop, there was a plenary discus-
sion on the definition and differential diagnosis of
cytotoxic and nonnasal NK/T-cell primary cutaneous
lymphomas, but some gray areas still remained. To
solve residual problems, a committee composed of 10
experienced dermatopathologists or hematopatholo-
gists (EB, MEK, DM, CJLMM, HKM-H, MP, NP, MS,
JW, RW) was appointed. They met on January 16 –18,
1999, at the Department of Human Pathology and
Oncology, University of Florence Medical School, Flo-
rence, (Italy). This report summarizes the results of
both the plenary and committee discussions. Forty-
eight cases of appropriate immunophenotype were
identified and included in the present study. Four of
these cases have been included in previous studies on
various lymphoma types.7–10
Clinical records and follow-up data through De-
cember 1999 were obtained from patients’ charts. The
principal parameters evaluated included age and gen-
der, extent of disease, spontaneous regression, symp-
toms at presentation, bone marrow involvement, cu-
taneous recurrences, extracutaneous progression of
disease, treatment, and follow-up duration (Table 1).
The TIA-1 and CD56 status was determined im-
munohistochemically on paraffin sections using the
antibodies TIA-1 (Coulter, Miami, FL) and 123C3 (Lab-
Vision, Fremont, CA), respectively. In previous studies,
other authors have shown that 123C3 reliably detects
CD56 expression in lymphomas on paraffin-embed-
ded tissues.5 Additional immunohistochemical data
were provided by the source institutions. Epstein–Barr
virus (EBV) infection was demonstrated using noniso-
topic in situ hybridization for EBV-encoded small
RNAs (EBERs) on paraffin-embedded material, as pre-
viously described,11 as well as by immunohistochem-
istry with antibodies against LMP-1 or by polymerase
chain reaction (PCR). The DNA used for gene rear-
rangement studies was extracted from frozen or par-
affin-embedded tumor tissue. T-cell receptor (TCR)
gene rearrangement was evaluated by a PCR assay
coupled with nondenaturing polyacrylamide gel elec-
trophoresis according to a method previously de-
scribed.12 Amplification of the TCR- chain locus V-J
junctional region was performed by using oligonucle-
otide primers specific for J1/2 paired with V2a, V9, and
V10. In some cases, DNA was digested with restriction
endonuclease BamHI, EcoRI, or HindIII, subjected to
electrophoresis on a 0.8% agarose gel, and transferred
to a nitrocellulose filter for Southern analysis using
hybridization with 32P-labeled DNA probes, according
to standard protocols.13,14 Rearrangements of the TCR
and immunoglobulin genes were evaluated using
probes that include a 1.0-kb germline Pst-EcoRI frag-
ment containing the first region (J1), the constant
region of TCR- gene (C), the TCR- gene, and JH
(heavy-chain joining region).15
RESULTS
Several groups with different clinical (Table 1) and
pathologic features were delineated among these 48
cases.
Cases 1–4: Aggressive, CD8, Epidermotropic, Cytotoxic
T-cell Lymphoma WHO: Not Recognized
Clinical features
This group included four male patients, 33– 82 years of
age (mean age, 62 years; median age, 76.5 years).
Three of the four patients presented with widespread,
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TABLE 1
Clinical Data and Follow-Up Information
Case
no.
Gender/
age Type of lesion
Sites of disease at
presentation Initial treatment Subsequent treatment Progression Outcome (mos)
1 M/33 Plaques, nodules Widespread PUVA-PR IFN-NR, TSEBI-NR, CT(CHOP)-NR Skin, oral mucosa, and systemic
involvement (sepsis)
DOD, 34
2 M/82 Nodules Widespread CT (COP) and RT-CR CT (unspecified) Skin and systemic involvement DOD, 17
3 M/59 Plaques Widespread Topical nitrogen mustard-CR CT (CHOP), RT, topical nitrogen mustard Skin and systemic involvement DOD, 28
4 M/74 Nodules Lower limb IFN and retinoids-PR CT (CHOP)-PR Skin and systemic involvement DOD, 10
5 M/16 Patches, plaques Widespread PUVA-CR N.A. Skin AWD, 24
6 M/30 Patches Lower limb PUVA-PR Topical steroids-NR CT (miltefusine)-PR Skin AWD, 36
7 F/77 Plaques Widespread PUVA-PR RT (TSEBI)-CR Skin AWD, 32
8 F/30 Patches Trunk PUVA-CR Nil Nil NED, 30
9 F/59 Patches, plaques Widespread PUVA-CR PUVA-PR Skin AWD, 144
10 F/54 Subcutaneous nodules Limbs Systemic steroids-CR CT(cyclophosphamide)-PR Skin AWD, 96
11 M/14 Subcutaneous nodules Limbs, buttocks CT (ACVBP)-CR Nil Nil NED, 15
12 F/55 Subcutaneous nodules Limbs Nil (spontaneous remission) Nil (spontaneous remission) Skin AWD, 60
13 M/36 Subcutaneous nodules Limbs Topical steroids-CR CT (CHOP, CDA, ara-C, others)-PR, RT
(TSEBI)-PR
Skin and systemic involvement
(hemophagocytic syndrome)
AWD, 24
14 M/53 Subcutaneous nodules Limbs Steroids and
hydroxychlorokine-NR
CT (mitoxantrone, etoposide, vincristine,
cyclophosphamide)-NR
Skin and systemic involvement
(pancytopenia, sepsis)
DOD, 9
15 F/56 Subcutaneous nodules Head, trunk, upper
limb
Steroids-NR CT (cyclophosphamide, CEOP)-NR Skin and systemic involvement
(pancytopenia, sepsis)
DOD, 24
16 M/10 Subcutaneous nodules Trunk, upper limb Steroids-NR CT (cyclophosphamide, CEOP)-NR Skin and systemic involvement
(pancytopenia, sepsis)
DOD, 5
17 M/76 Subcutaneous nodules Limbsa N.A. N.A. Skin AWD, 24
18 F/44 Subcutaneous nodules Lower limb CT (CHOP)-NR CT (VIM2, ara-C)-NR Skin and systemic involvement (liver
and lung)
DOD, 17
19 F/8 Subcutaneous nodules Trunk Cyclosporine-PR CT (unspecified)-NR Skin and systemic involvement DOD, 23
20 F/73 Subcutaneous nodules Lower limb, buttocks CT (CHOP)-PR RT-PR, CT (methotrexate)-PR Skin and systemic involvement (liver) DOD, 12
21 F/33 Subcutaneous nodules Limbs, buttocks Steroids and retinoids-PR N.A. Skin and systemic symptoms (malaise,
fatigue, and fever)
AWD, 12
22 M/53 Nodule Upper limba N.A. N.A. N.A. N.A.
23 F/27 Nodules Head, trunk Nil (spontaneous remission) N.A. N.A. N.A.
24 F/43 Nodules Upper limb CT (CHOP)-CR CT (unspecified)-PR Skin,b AWD, 10
25 M/71 Nodules Trunk, limbs CT (CHOP)-CR CT (methotrexate)-CR CNS DOC (stroke), 3
26 M/60 Nodules Head CT (VICOP-B)-NR CT (unspecified)-NR Skin and systemic involvement (bone
marrow)
DOD, 8
27 M/60 Papules, plaques Widespread CT (fludarabine)-CR Nil Nil NED, 16
28 M/57 Plaques, nodules Widespread CT (unspecified)-PR CT (unspecified)-PR Skin N.A.
29 F/47 Plaques Head, lower limb RT and CT (CHOP)-CR IFN and CT (vincristine, chlorambucil)-
PR
Skin and systemic involvement (lymph
nodes, CNS)
DOD, 31
30 M/41 Plaques Lower limba RT-CR Nil Nil NED, 44
31 M/38 Plaques, nodules Widespread Nil CT (PROMACE-CYTABOM) and
allogeneic BMT-CR
Skin and systemic involvement (bone
marrow and blood)
DOD, 22
32 M/83 Plaques, nodules Trunk CT (mini-CEOP)-CR CT (unspecified)-NR Skin and systemic involvement (bone
marrow and blood)b, c
DOD, 10
33 M/80 Plaques, nodules Head, trunk CT (COP)-NR CT (unspecified)-PR Skin and systemic involvement (bone
marrow)
DOD, 20
34 M/51 Nodules Head, trunk N.A. N.A. N.A. N.A.
35 M/55 Plaques, nodules Head, trunk CT (MACOP-B)-CR IFN, CT (chlorambucil), and steroids-NR,
autologous BMT-CR
Skin and systemic involvement N.A.
36 M/61 Plaques, nodules Trunk, limbs CT (CEOP)-CR RT and CT (MACOP-B)-CR Skin and systemic involvement (bone
marrow, blood, and lymph nodes)
DOD, 37
37 M/58 Plaques, nodules Widespread CT (CHOP)-PR CT (unspecified)-NR Skin and systemic involvement (testis
and bone marrow)
DOD, 16
38 M/54 Plaques Trunk, lower limb Antibioticd CT (CHOP)-CR Skin and systemic involvement (CNS) DOD, 17
39 F/72 Nodule Head RT-CR Nil Nil NED, 36
40 M/43 Nodule Upper limb N.A. N.A. N.A. N.A.
41 M/63 Nodules Limbs, trunk Nil (spontaneous remission) Nil Skin NED, 12
42 F/60 Nodules Limbs, trunk Steroids and clofazimine-PR N.A. Skin AWD, 60
43 F/63 Plaques Lower limb RT and CT
(cyclophosphamide)-CR
Nil Nil NED, 36
44 M/60 Nodules Limbse RT-NR, CT (CDA, CHOP)-PR Skin and systemic involvement (lymph
nodes)
DOD, 18
45 F/38 Plaques, nodules Trunk, limbsf CT (unspecified)-CR Nil N.A.
46 F/76 Plaques Limbs Nil (spontaneous remission) RT-PR Skin and systemic involvement (lymph
nodes, soft tissues, CNS)
DOD, 11
47 M/77 Nodule Head Surgery and RT-CR N.A. Skin and systemic involvement
(pharyngeal mass)
DOD, 11
48 M/39 Nodule Lower limb RT-CR RT  CT (CHOP)-PR Skin and systemic involvement (soft
tissues and bone marrow)
DOD, 12
AWD: Alive with disease; BMT: bone marrow transplantation; CNS: central nervous system; CR: complete remission; CT: chemotherapy; DOD: dead of disease; NR: no response; PR: partial remission; RT: radiotherapy;
N.A.: information not available; NED: no evidence of disease; IFN: -2 recombinant interferon; TSEBI: total skin electron beam irradiation; ara-C: cytosine arabinoside; PUVA: psoralen ultraviolet light; CHOP:
cyclophosphamide, doxorubicin, vincristine, and prednisone.
a Myelodysplastic syndrome.
b Polypoidal thickening of the nasal/paranasal mucosa demonstrated at computed tomographic scan; biopsy not performed.
c Gastric carcinoma.
d Treatment for concomitant Borrelia Burgdorferi infection.
e Hairy cell leukemia.
f Lymphomatoid granulomatosis Epstein–Barr virus infection.
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disseminated plaques and/or nodules that had devel-
oped within a few weeks, often with hemorrhage and
central ulceration (Fig. 1A). One patient presented
with nodular lesions on the right leg. The initial treat-
ment was skin oriented in two patients (treated with
psoralen ultraviolet light [PUVA] and topical chemo-
therapy). The other two patients were treated with
multiagent chemotherapy (cyclophosphamide, doxo-
rubicin, vincristine, and prednisone [CHOP]), radio-
therapy (total skin electron beam irradiation [TSEBI],
and with -2 recombinant interferon and etretinate.
Despite the initial response to treatment, the disease
course was very aggressive, with rapid extracutaneous
spread and death (sepsis). All patients died of disease
within 3 years from diagnosis (survival, 10 –34 months;
mean, 22.2 months; median, 22.5 months).
Histologic features
The cutaneous specimens showed no consistent epi-
dermal modifications, the epidermis being atrophic in
two cases (one of which displayed central ulceration)
and acanthotic in the other two. Single necrotic kera-
tinocytes were detected at the dermal-epidermal junc-
tion. In one case, the confluence of basilar necrotic
keratinocytes gave rise to a dermal-epidermal cleft,
reminiscent of pityriasis lichenoides et varioliformis
acuta. Moderate to marked spongiosis was always ob-
served, with blistering in two cases. Tumor cells
showed striking epidermotropism, both of single cells
and tiny collections (Fig. 1B). Colonization of the basal
cell layer by neoplastic cells in a linear configuration
and involvement of the entire epidermis in a pagetoid
fashion were observed. They were particularly evident
at the periphery of the lesions, whereas Pautrier mi-
croabscesses were not seen. In three cases, the neo-
plastic infiltrate presented a lichenoid pattern, obscur-
ing the dermal-epidermal junction, at the papillary
and superficial reticular dermis, whereas a patchy/
nodular perivascular infiltrate was found in the mid-
lower reticular dermis. Conversely, in one case, the
neoplastic infiltrate was almost confined to the epi-
dermis, in a pagetoid pattern. Subcutaneous involve-
ment was documented in two cases. Neoplastic cells
were medium to large, with an irregular (pleomorphic)
or round (blastic) nucleus (Fig. 1C). Adnexal involve-
ment by tumor cells (both of pilosebaceous units and
eccrine ducts) was seen in three of four cases. Angio-
centricity and angioinvasion were observed in two
cases.
Immunophenotype
In all four cases, the tumor cell phenotype was CD3,
CD4, CD8, CD45RA, CD45RO, TIA-1, bcl-2,
MIB-1 ( 90% of tumor cells). CD56 expression was
observed in three of the four cases. Granzyme B was
expressed in two cases, and epithelial membrane an-
tigen (EMA) in one case. Among the three cases in
which frozen tissue was available for analysis, one
case was CD2/CD5/CD7, one case was CD2/
FIGURE 1. Aggressive, CD8, epidermotropic, cytotoxic T-cell lymphoma.
(A) Typical clinical presentation with plaques and nodules, often with hemor-
rhage and central ulceration. (B) Tumor cells show striking epidermotropism
within a markedly hyperplastic epidermis. (C) Neoplastic cells are medium to
large in size, with pleomorphic or sometimes roundish nuclei.
Cytotoxic/NK Cell Cutaneous Lymphomas/Santucci et al. 613
CD5/CD7, and the third case was CD2/CD5/
CD7. Rearrangement of the TCR- gene was dem-
onstrated in the three cases investigated.
Cases 5–9: Mycosis Fungoides, Cytotoxic
Immunophenotype Variant (WHO: Mycosis Fungoides)
Clinical features
This group included five patients (three women and
two men), 16 –77 years of age (mean age, 42.4 years;
median age, 44.5 years). These patients were charac-
terized by the typical clinical presentation and course
of mycosis fungoides. All patients presented with ery-
thematous and scaly, sometimes poikilodermatous,
patches, and/or plaques. The initial treatment con-
sisted of PUVA in all cases. The disease showed an
overall indolent, slowly progressing course, with re-
currences controlled by generally nonaggressive treat-
ments (four of five patients are alive with disease and
one has no evidence of disease, with a follow-up of
24 –144 months; mean, 53.2 months; median, 32
months).
Histologic features
The skin specimens were characterized by a moder-
ately dense lympho(histio)cytic infiltrate around
blood vessels of the superficial and deep dermis. The
infiltrating cells filled a widened papillary dermis and
were arranged in a band-like configuration. Medium
to large cerebriform cells were found within the epi-
dermis, singly or in tiny collections. The epidermis
was usually acanthotic, with focal orthokeratotic or
parakeratotic scales. Spongiotic microvesiculation was
evident in one case in which the histology was remi-
niscent of aggressive, CD8, epidermotropic, cyto-
toxic T-cell lymphomas. In one case, epidermotropic
changes were scant. Papillary dermal fibrosis was of-
ten found between the dermal band-like infiltrate and
the overlying epidermis. Cerebriform and pleomor-
phic lymphocytes were constantly present in large
numbers in the dermal infiltrate intermingled with
inflammatory cells, especially plasma cells and eosin-
ophils. Extravasation of erythrocytes was sometimes
seen.
Immunophenotype
In all cases, the neoplastic cells expressed the CD2,
CD3, CD4, CD5, TIA-1 phenotype. CD8 posi-
tivity was detected in three cases, and two cases ex-
pressed the CD56 antigen. One case was CD45RO/
CD45RA and two cases were CD45RO/CD45RA.
In the case showing prominent spongiotic microve-
siculation and a histologic profile reminiscent of ag-
gressive, CD8, epidermotropic, cytotoxic T-cell lym-
phomas, all epidermotropic tumor cells were positive
for the CD30 antigen, whereas there was total nega-
tivity of dermal tumor cells for CD30 expression.
Cases 10–21: Subcutaneous Panniculitis-like T-cell
Lymphoma (WHO: Subcutaneous Panniculitis-like T-cell
Lymphoma)
Clinical features
This group included 12 patients (7 women and 5 men),
8 –76 years of age (mean age, 42.6 years; median age,
53 years). All patients showed a typical clinical presen-
tation mimicking panniculitis: indurated, painful, sub-
cutaneous plaques and/or nodules mostly located on
the lower limbs, frequently with ulceration (Fig. 2A)
and fever. Most patients were treated initially with
antiinflammatory/immunosuppressive regimens (ste-
roids with or without low-dose cyclophosphamide or
hydroxychlorokine or retinoids). Three patients were
treated with multiagent chemotherapy (CHOP [cyclo-
phosphamide, doxorubicin, vincristine, prednisone],
ACVBP [doxorubicin, cyclophosphamide, vindesine,
bleomycin, prednisone]) and one patient was not
treated due to spontaneous remission of skin lesions.
The clinical behavior was rapidly progressive in six
cases, with cutaneous dissemination, extracutaneous
spread, sepsis, and death despite aggressive chemo-
therapy (CHOP, CEOP [cyclophosphamide, epiru-
bicine, vincristine, prednisone], VIM2, cytosine arabi-
noside). Two additional patients, although still alive
with disease, experienced systemic symptoms includ-
ing hemophagocytic syndrome. Conversely, the clini-
cal course was indolent in four patients, three of
whom are alive with local disease. These patients ex-
perienced cutaneous recurrences, sometimes under-
going spontaneous remission, with long-standing re-
missions even after mild treatments. The last patient is
alive with no evidence of disease after 15 months of
follow-up.
Histologic features
All cases were characterized by a predominantly sub-
cutaneous atypical lymphoid infiltrate. Involvement of
the subcutis, without any dermal extension, was ob-
served in two cases. A slight (five cases) to moderate
(five cases) involvement of the reticular dermis,
mainly perivascular in location, was observed in 10
cases. The involvement of the papillary dermis, with
epidermotropic phenomena, was observed as a major
feature in one case and was less prominent in three
additional cases. The pathognomonic histopathologic
feature of this group of lymphomas was infiltration of
fat lobules by neoplastic cells in a lace-like fashion
resembling a lobular panniculitis in eight cases (Fig.
2B) and a mixed panniculitis (lobular plus septal) in
four cases. Subcutaneous septa were rarely thickened.
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FIGURE 2. Subcutaneous panniculitis-like T-cell lymphoma. (A) Characteristic clinical presentation mimicking panniculitis with plaques and nodules located on
the lower limbs, frequently with ulceration. (B) The neoplastic infiltrate predominantly involves subcutaneous fat in a lace-like fashion resembling a lobular
panniculitis. (C) Rimming of individual adipocytes by neoplastic cells and karyorrhectic phenomena are common features. (D) TIA-1 positivity is observed in neoplastic
cells. (E) Tumor cells show a positive immunoreaction for CD8.
Cytotoxic/NK Cell Cutaneous Lymphomas/Santucci et al. 615
The rimming of individual adipocytes by neoplastic
cells was a common feature (Fig. 2C). The neoplastic
infiltrate was composed of pleomorphic lymphocytes
of variable size, with an irregular, hyperchromatic nu-
cleus. A predominance of small to medium cells was
observed in all cases and large transformed lymphoid
cells were seen in six cases. A characteristic feature
was the presence of karyorrhectic phenomena, which
were seen in every case and were prominent in 10
cases. Fat necrosis was frequent with foamy or finely
vacuolated histiocytes. Small cysts lined by amor-
phous eosinophilic material were documented in five
cases. Multinucleated giant cells were seen in five
cases. Scattered plasma cells were rarely seen. Neu-
trophils and eosinophils were absent, except for two
cases in which neutrophilic microabscesses were
found within necrotic foci. A slight to moderate angio-
centricity occurred in eight cases and angioinvasion of
small blood vessels was present in five cases.
Immunophenotype
In all cases, the tumor cell phenotype was CD2, CD3,
CD45RO, CD43, and TIA-1 (Fig. 2D). Seven cases
expressed the T-suppressor cell antigen, CD8 (Fig. 2E),
and possible coexpression of CD4 was seen in two of
these cases. Two additional cases were CD4/CD8,
whereas the neoplastic cells did not express either CD4
or CD8 in three cases. CD56 was positive in 7 of 12 cases.
Among the five cases with frozen tissue available for
immunohistochemistry, three were positive for CD5 an-
tigen and all cases were negative for CD7. Perforin and
Granzyme B (GrB) cytoplasmic staining was observed in
all four tested cases. Weak focal staining for CD30 was
noted in two of seven cases. All nine cases tested ex-
pressed TCR antigens. Two cases proved to be /
(F1) T-cell lymphomas and the other seven were de-
rived from / T cells (TCR1). All / cases were
CD56, whereas none of the two / lymphomas ex-
pressed CD56. A significant difference in the tumor cell
phenotype was observed according to the exclusive sub-
cutaneous or subcutaneous and dermal involvement by
neoplastic cells. Among cases with dermal extension
tested for TCRs, seven were TCR1 and one was F1.
Clonal TCR gene rearrangements were documented in
the six cases investigated. Clonal rearrangement of
TCR- was shown in five lymphomas, including 1 /
and 4 / lymphomas. Clonal rearrangements of the
TCR-gene were confirmed by PCR analysis in 1 /
lymphoma showing a clonal V2 rearrangement. None of
the three cases tested for EBER or LMP-1 was positive for
EBV.
Cases 22–24: NK/T-Cell lymphoma, Nasal Type (WHO:
Extranodal NK/T-cell Lymphoma, Nasal Type)
Clinical features
This group included two females (age 27 and 43 years,
respectively) and one male aged 53 years. The male
patient, affected by a myelodysplastic syndrome, pre-
FIGURE 3. Natural killer T-cell lymphoma, nasal type. (A) Clinical presenta-
tion with a single nodular lesion with hemorrhage and central ulceration on a
finger. (B) Prominent zonal tumor cell necrosis, with angiocentric and angiode-
structive phenomena of small to medium-sized vessels, is frequently observed.
(C) Epstein–Barr virus (EBV)-encoded RNA in situ hybridization shows that
neoplastic cells are EBV positive.
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sented with a single nodular lesion on the left ring
finger (Fig. 3A). Another patient developed multiple
cutaneous nodules that underwent spontaneous re-
mission. Staging was negative. These two patients
were lost to follow-up. The third patient presented
with multiple, rapidly growing cutaneous nodules on
the left arm and other lesions appeared on the legs 6
months later, some of which underwent spontaneous
remission. Approximately 6 months after diagnosis, a
computed tomographic (CT) scan documented a
polypoidal thickening of the nasal and paranasal
(frontal sinus) mucosa. Bone CT scan and bone mar-
row biopsy were negative. Following aggressive mul-
tiagent chemotherapy courses, the lesions underwent
almost complete remission, but the disease recurred.
The patient died with disseminated disease 18 months
from diagnosis.
Histologic features
In two cases, the lymphomatous infiltrate was diffuse,
involving the entire dermis and the subcutis. In the
last case, tumor cells were localized mainly to the deep
reticular dermis and subcutis. The neoplastic infiltrate
was composed of small to medium-sized pleomorphic
lymphocytes with irregular nuclei, inconspicuous nu-
cleoli, and scant cytoplasm. Neither polymorphonu-
clear leukocytes nor plasma cells were seen, whereas
small numbers of reactive lymphocytes, intermingled
with tumor cells, were observed in all cases. In one
case, reactive lymphocytes were seen in the epidermis
and skin appendages. Apoptosis was prominent in two
cases. Zonal tumor cell necrosis, focal or confluent,
with angiocentric and angiodestructive phenomena of
small to medium-sized vessels was a prominent fea-
ture in all specimens (Fig. 3B). The vessels of the deep
reticular dermis were massively infiltrated by atypical
lymphoid cells and surrounded by extensive areas of
coagulative necrosis, with only cuffs of surviving lym-
phoma cells around the blood vessels. The involved
vessels showed endothelial swelling and onion skin
thickening of the wall, with fibrin deposition and nu-
clear debris. Extensive epidermal ulceration was ob-
served in one case.
Immunophenotype
All cases were CD3, CD3, CD56, CD57, CD4,
CD45RO, CD45RA, and TIA-1. Two of three cases
were CD8. In one case in which frozen tissue was
available, tumor cells were CD2/CD94/NKp46/
CD5/CD7. CD30 expression was found in a minor-
ity of tumor cells (30%) in two of three cases. In all
cases, B-lineage markers (CD20, CD79a) were nega-
tive. None of the cases showed clonal TCR rearrange-
ment by PCR for TCR-. In the two cases tested, neo-
plastic cells were EBER (in situ hybridization and
PCR; Fig. 3C) and LMP1.
Cases 25–36: CD4, NK Cell Lymphoma (WHO: Blastic
NK Cell Lymphoma)
Clinical features
This group comprised 12 patients (11 males and only
1 female), 38 – 83 years of age (mean age, 58.7 years;
median age, 58.5 years). All patients presented with
rapidly extending, multiple plaques and/or nodules in
noncontiguous skin sites (Fig. 4A). Nine patients re-
ceived multiagent chemotherapy as the initial treat-
ment (mostly CHOP-like regimens) and one patient
received chemotherapy and radiotherapy (TSEBI). In
one case, characterized by a localized lesion of the
lower limb, radiotherapy alone was given. In one case,
no treatment was given initially. There were no data
concerning treatment in one case. Complete remis-
sion was achieved after the initial treatment in 6 of 10
treated patients. For seven patients, the course was
characterized by skin disease recurrence and systemic
involvement (bone marrow, blood, lymph nodes, cen-
tral nervous system [CNS], and nasopharynx, variably
involved) despite aggressive multiagent chemotherapy
and autologous bone marrow transplantation in two
patients. Two patients achieved stable complete re-
mission and currently have no evidence of disease.
Clinical information concerning the current status is
not available for three cases.
Histologic features
The lymphomatous infiltrate was diffuse, involving the
entire thickness of the dermis in five cases (Fig. 4B),
with subcutaneous extension in two cases. In seven
other cases, tumor cells were arranged in a patchy-
nodular profile at the dermal level, with subcutaneous
involvement in six cases. In nine cases, single cells or
rows of neoplastic cells infiltrated the dermal collagen
bundles in an “Indian file” or reticular pattern (Fig.
4C). In most cases (8 of 12), a clear-cut grenz zone,
with edema of the papillary dermis (three cases), was
observed. Focal epidermotropic phenomena were ob-
served in three cases. Cytologically, a variable mixture
of small-medium to large pleomorphic lymphocytes
was noted in nine cases (Fig. 4D). In the other three
cases, the neoplastic infiltrate was monomorphous,
composed of medium to large blastic lymphocytes.
Neither polymorphonuclear leukocytes nor plasma
cells were seen, whereas small numbers of reactive
lymphocytes, intermingled with tumor cells, were ob-
served. Apoptotic phenomena were not prominent.
Angiocentric and angiodestructive features of small to
medium-sized vessels were often observed, but were
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FIGURE 4. CD4, natural killer cell lymphoma. (A) Clinical presentation with multiple cutaneous erythematous nodules. (B) Diffuse lymphomatous infiltrate
involving the entire dermis. (C) Single cells or rows of neoplastic cells infiltrate the dermal collagen bundles in an Indian file or reticular pattern. (D) The neoplastic
infiltrate is composed of medium to large lymphocytes. (E) Tumor cells are diffusely positive for CD56.
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not prominent. There were no obvious areas of intra-
tumoral necrosis.
Immunophenotype
All cases were CD4, CD56 (Fig. 4E), bcl-2,
CD43, CD3, CD8, F1, TCR1, CD30. All but
one case were CD45RA/CD45RO. CD3 (poly-
clonal anti-CD3) was expressed in four of seven tested
cases. On frozen sections, all eight cases were CD123/
IL3R, CD94, NKp46. Eight of 12 cases were
CD2/CD5/CD7, 3 cases were CD2/CD5/
CD7, whereas the last case was CD2/CD5/CD7.
The CD57 antigen was found in two of the six tested
cases. In eight of the nine cases tested, a high prolif-
erative activity of tumor cells (MIB-1 50%) was
found. TIA-1 was negative in all but two cases. Among
the 10 cases in which CD68 expression was evaluated,
7 cases gave a positive reaction in a high percentage of
tumor cells. CD34 was negative in the eight tested
cases. B-cell–associated antigens (CD20, CD21, CD22,
CD79a) were negative in all cases. None of the 10 cases
tested for EBER and LMP-1 was positive for EBV. None
of the nine cases tested showed TCR gene rearrange-
ments.
Case 37: Blastoid NK Cell Lymphoma (WHO: Blastic NK
Cell Lymphoma)
Clinical features
This patient was a 58-year-old man who presented
with multiple plaques and nodules disseminated on
the skin. At presentation, systemic symptoms were
absent and the patient’s staging workup was negative.
Following aggressive chemotherapy courses (CHOP),
the patient experienced partial remission. Shortly
thereafter, the disease pursued a fulminant course
with bone marrow and testicular involvement. The
patient died 16 months after diagnosis.
Histologic features
The tumor cells were located mainly in the middle and
deep dermis, sparing the subepidermal region, and
infiltrated the collagen bundles in an interstitial pat-
tern of growth. The infiltrate was monomorphous and
composed of medium to large-sized cells with round
nuclei and fine diffuse chromatin.
Immunophenotype
The neoplastic cells were CD3, CD4, CD8,
CD45RO, CD45RA, CD56, TIA-1, GrB, F1,
TCR1, EBER, and LMP-1. A focal positivity for
CD68 was also demonstrated. B-cell markers (CD20,
CD79a) were negative.
Case 38: Intravascular NK-like Lymphoma (WHO: Not
Recognized)
Clinical features
The patient, a 54-year-old man, presented with ery-
thematous plaques on the trunk (Fig. 5A) and thighs,
leukopenia (with CD4 T-cell depletion), and weight
loss. Borrelia burgdorferi was detected serologically
and in the skin by enzyme-linked immunosorbent
assay and PCR, respectively. Complete remission of
skin lesions, with simultaneous conversion to negative
PCR for Borrelia, was achieved after five CHOP
courses. However, shortly after the resolution of the
cutaneous lesions, clinical and CT scan signs of CNS
involvement appeared and the patient died of disease
17 months after diagnosis.
Histologic features
The skin specimen was characterized by a vascular-
occlusive process involving venules, capillaries, and
arterioles at the dermal and subcutaneous levels. Af-
fected vessels were dilated by an accumulation of non-
cohesive, large atypical blast-like cells (Fig. 5B), often
mixed with abundant fibrin. Vascular occlusion, with-
out significant recanalization, was often observed. The
epidermis demonstrated no significant changes.
Immunophenotype
The tumor cell phenotype was CD3, CD56 (Fig.
5C), TIA-1, GrB, CD30, MIB-1 (100% of tumor
cells), EBER (Fig. 5D), LMP1, CD4, CD8,
CD20, CD79a, CD57, CD68, and bcl-2.
Cases 39–48: Cytotoxic, Peripheral T-cell Lymphoma
(WHO: Peripheral T-cell Lymphoma, Unspecified)
Clinical features
This group included 10 patients (5 women, 5 men)
38 –77 years of age (mean age, 59.1 years; median age,
61.5 years). Patients presented with isolated/localized
or disseminated nodules and/or plaques. The treat-
ment was variable, mostly depending on the distribu-
tion of skin lesions (surgery and/or radiotherapy in
patients with isolated/localized lesions, single or mul-
tiagent chemotherapy in patients with disseminated
lesions). In this group, two clinical subsets were de-
lineated. One subset was characterized by extracuta-
neous spread (lymph nodes, pharynx, soft tissues,
CNS, bone marrow) and death despite treatment with
multiagent chemotherapy (CHOP or CHOP-like). In
the second group, the patients showed a chronic
course, with spontaneous remission of disease in one
case. Neither the variable distribution of skin lesions
at presentation (isolated/localized vs. disseminated)
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nor the aggressiveness of the initial treatment corre-
lated with the clinical course.
Histologic features
This group was characterized by a proliferation of pleo-
morphic lymphocytes of variable size (small to medium
cells in three cases, medium to large cells in six cases,
and large, blast-like cells in one case). The pattern of
infiltration was heterogenous, ranging from patchy
perivascular (three cases) to diffuse dermal involvement
(two cases), to diffuse in the dermis with extensive sub-
cutaneous involvement (three cases), to mainly subcu-
taneous with slight dermal involvement (two cases).
Immunophenotype
All cases expressed CD3, all but two cases were TIA-1,
and 5 of 10 were CD56 (including the 2 TIA-1 cases).
Three cases were CD4, three cases CD8 and the five
CD4, CD8 cases stained with F1 (two cases) or with
TCR-1 (two cases). The CD45RO antigen was diffusely
expressed in one-half of the cases. Among the six cases
in which frozen material was available, three cases ex-
pressed either CD2, CD5, or CD7. Two cases showed a
diffuse positivity ( 70% of tumor cells) for the CD30
antigen. One of these two patients experienced sponta-
neous remission and is alive with no evidence of disease
1 year from diagnosis. All but one case was negative for
B-cell–associated markers. The remaining case was im-
munoreactive for CD79a, even though it lacked immu-
noreactivity for CD20, was positive for F1, and lacked
clonal rearrangement for Ig heavy chains by PCR. None
of the five cases tested for EBER and/or LMP-1 was
positive for EBV.
DISCUSSION
The spectrum of cutaneous cytotoxic lymphomas was
heterogenous with regard to clinical presentation,
morphologic and immunophenotypic features, asso-
FIGURE 5. Intravascular natural killer-like lymphoma. (A) The patient presented with erythematous plaques on the trunk. (B) Affected vessels are dilated by an
accumulation of noncohesive, large atypical blast-like cells. (C) Tumor cells are positive for CD56. (D) Epstein–Barr virus (EBV)-encoded RNA in situ hybridization
shows that neoplastic cells are EBV positive.
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ciation with EBV, and clinical course. Taking into ac-
count these features, several categories were identi-
fied. Their salient features are summarized in Table 2,
based on information from the current study and the
literature.
Information on aggressive, CD8, epidermo-
tropic, cytotoxic T-cell lymphomas is very limited.
Only sporadic cases of mycosis fungoides, pagetoid
reticulosis, or other types of T-cell lymphomas ex-
pressing a CD8, cytotoxic phenotype have been de-
TABLE 2
Summary of the Major Types of Cutaneous Lymphomas Expressing the Cytotoxic-Associated Marker TIA-1
and/or the Natural Killer Cell Marker CD56a
Characteristics
Aggressive, CD8,
epidermotropic,
cytotoxic T-cell
lymphoma
Mycosis fungoides,
cytotoxic
immunophenotype
variant
Subcutaneous
panniculitis-like T-cell
lymphoma
NK/T-cell lymphoma,
nasal type
CD4, NK cell
lymphoma
Blastoid NK-cell
lymphoma
Intravascular NK-like
lymphoma
Age Middle-aged or
elderly adults
Middle-aged or
elderly adults
Middle-aged adults,
children
Adults Adults Adults Adult
Gender M  F M  F F  M M  F M  F M M
Clinical presentation Patches, plaques, and
nodules, often with
hemorrhage and
ulceration
As typical mycosis
fungoides
Mimicking panniculitis:
indurated, painful
subcutaneous plaques or
nodules, mostly located
on the lower limbs,
common ulceration of
lesions and fever
Multiple cutaneous
nodules commonly
followed by
systemic
dissemination
(upper
aerodigestive tract,
soft tissues, testis,
and gastrointestinal
tract); sometimes
involvement of
multiple extranodal
sites at
presentation
Multiple cutaneous
papules, plaques,
and nodules in
noncontiguous skin
sites
Disseminated plaques
and nodules on the
skin; sometimes
systemic disease at
presentation
Disseminated,
cutaneous
erythematous
plaques
Histologic features Lichenoid infiltrate
composed of
medium/large
pleomorphic T
cells, with linear
and pagetoid
epidermotropism,
spongiosis, and
blistering, variable
numbers of
necrotic
keratinocytes at the
dermal-epidermal
junction.
As typical mycosis
fungoides
Variably sized pleomorphic
lymphocytes infiltrating
subcutis in a lace-like
fashion, with rimming of
adipocytes by neoplastic
cells; karyorrhexis and fat
necrosis common;
granulomatous reaction
and erythrophagocytosis
seldom observed;
frequent dermal
involvement in TCR1
cases.
Proliferation of
variably sized
pleomorphic cells,
with prominent
angiocentricity,
angiodestructive
growth, and
extensive necrosis.
Variably sized
pleomorphic
lymphocytes or,
more rarely,
monomorphic
medium-large blasts
in an “Indian file” or
reticular pattern;
angiocentric and/or
angiodestructive
features frequently
observed, never
prominent.
Monomorphous
infiltrate composed
of medium-large–
sized cells
infiltrating collagen
bundles in an
interstitial pattern
Intravascular
accumulation of
large atypical blast-
like cells mixed
with abundant
fibrin
Most common
immunophenotype
CD3, CD4, CD8,
CD45RA,
CD45RO, TIA-1,
bcl-2, MIB-1(
90%), CD56/,
CD2/, CD5/,
CD7/
CD3, CD4,
CD8/,
CD45RA/,
CD45RO/,
TIA-1, CD56/
, CD2, CD5
CD2, CD3, CD3,
CD45RO, CD43, TIA-
1/perforin/GrB, CD8/
, CD4/, CD56/,
CD5/, CD7.
/(TCR1) 
/(F1) (Europe), /
(F1)/(TCR 1)
(USA)
CD2, CD3,
CD3, CD4,
CD8/,
CD45RO,
CD45RA, TIA-1,
CD56, CD57,
CD16
CD4, CD56, bcl-
2, CD43, CD3,
CD3, CD8,
CD45RA,
CD45RO, CD5,
CD2/, CD7/,
F1, TCR1,
CD30, CD57/,
MIB-1 ( 50%)
TIA-1/, CD68/
, CD34
CD2/, CD3,
CD3, CD4,
CD8, CD45RO,
CD45RA, CD56,
TIA-1, GrB,
F1, TCR1,
TdT/
CD3, CD56, TIA-
1, GrB, CD30,
MIB-1 (100%),
CD4, CD8,
CD57, CD68,
bcl-2
TCR genes Rearranged (TCR) Rearranged Rearranged Germline Germline Germline N.T.
Association with EBV Absent Absent Absent Present ( 90%) Absent Absent ?
Clinical behavior Rapidly progressive
dissemination (oral
cavity, testis, lung,
CNS, soft tissues;
sparing of lymph
nodes) and fatal
outcome (mean
survival time 32
mos)
As typical mycosis
fungoides
Frequent dissemination of
skin lesions and systemic
spread to bone marrow,
lung, liver, commonly
accompanied by sepsis
and hemophagocytic
syndrome; more rarely,
indolent course with
spontaneous remission
Aggressive, with early
dissemination;
common
recurrences despite
initial response to
chemotherapy
Aggressive, with rapid
dissemination to
bone marrow
(leukemia /) and
fatal outcome
Aggressive, with
systemic
involvement and
death
CNS involvement and
death
Treatment guidelines Chemotherapy
(purine analoges)
with/without
radiotherapy;
allogeneic
minitransplant
(second line)
As typical MF
(PUVA, topical
chemotherapy)
Chemotherapy (CHOP-like
or third-generation
regimens, possibly
followed by allogeneic
BMT) with/without
radiotherapy
Chemotherapy (CHOP-like or third-generation regimens), possibly followed by autologous or allogeneic
BMT with/without radiotherapy; radiotherapy on isolated lesions.
NK: natural killer cell; N.T.: not tested; BMT: bone marrow transplantation; TCR: T-cell receptor; CNS: central nervous system; EBV: Epstein-Barr virus infection.
a Based on data from the current series and from cases reported in the literature.
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scribed.16 –33 Even the EORTC classification in its cur-
rent form does not include CD8 cytotoxic T-cell
lymphomas neither in a well defined nor provisional
category.2 However, Berti et al.8 drew attention to
these tumors and suggested that CD8 cytotoxic T-
cell lymphomas represent a distinctive type of cuta-
neous T-cell lymphoma with an aggressive clinical
behavior.8 The results of our study confirmed those of
Berti et al.8 concerning the distinctive clinical presen-
tation and course, histology, and immunophenotypic
features of neoplastic cells of this peculiar type of
cutaneous T-cell lymphoma. In addition, we demon-
strated that these cutaneous T-cell lymphomas also
express the CD56 antigen, a finding not previously
reported. The T-cell origin and the clonality of this
neoplasm were confirmed by the rearrangement of the
TCR- gene in the three cases investigated. The course
of the disease is characterized by rapidly progressive
dissemination and death, despite the use of aggressive
multiagent chemotherapy regimens. It is noteworthy
that the systemic spread did not involve the lymph
nodes, but involved the oral cavity (one case), the soft
tissues of the centrofacial region (one case), and un-
usual sites (lung, testis, or CNS) accompanied by sep-
sis in one case. This may be attributed to the CD56
phenotype, which is associated with homing to ex-
tranodal sites.
Aggressive therapeutic modalities were ineffective
in the management of these patients. Therefore, new
strategies are needed. In this respect, two main points
should be taken into account. First, the course of the
disease is frequently associated with severe immuno-
deficiency. Therefore, neither TSEBI nor aggressive
polychemotherapy regimens are likely to achieve
long-standing clinical responses. When possible, an
allogeneic minitransplant instead of autologous bone
marrow transplantation may be suggested. Alterna-
tively, the use of purine analogs devoid of high immu-
nosuppressive capacity (like gemcitabine, which was
used in aggressive cutaneous T-cell lymphoma cas-
es34) may be proposed, possibly associated with local
radiotherapy. Second, as suggested by Berti et al.,8 the
putative Th1-like cytokine profile of these aggressive
CD8 cutaneous T-cell lymphoma should discourage
treatments that increase Th1 responses (e.g., retinoids
or interferon alpha). Extreme caution should be used
for such regimens.
Concerning mycosis fungoides, the cytotoxic im-
munophenotype variant, these cases were character-
ized by the typical clinical evolution, histology, and
course of mycosis fungoides. If there are immunophe-
notypic similarities with CD8 aggressive lympho-
mas, cytotoxic mycosis fungoides has to be regarded
as a phenotypic, and not a clinicopathologic, variant
of mycosis fungoides and should be treated nonag-
gressively according to well established guidelines
(PUVA, topical chemotherapy).
Subcutaneous panniculitis-like T-cell lymphoma
(SPTCL), currently included as a provisional entity in
both the REAL classification35 and the EORTC classi-
fication2 for primary cutaneous lymphomas, has been
incorporated as an entity in the WHO classification.2
The 12 cases in the current series exhibited the typical
features as described in the more than 60 cases re-
ported to date.36 –59 In our series, two phenotypic sub-
sets can be delineated: TCR-//CD56 and //
CD56. In agreement with previous observations,58
these phenotypic subsets correlated with the presence
or absence of dermal invasion. All but one case with
dermal extension were //CD56. Although a lim-
ited number of SPTCLs have been investigated for TCR
expression, earlier studies from Europe and Eastern
countries documented a prevalent / TCR expression
similar to that found in the current, study.40,46,55,60 – 62
American studies have emphasized that the majority
of SPTCL cases expressed / TCRs.57,58 We do not
know the reasons for the discrepancy between the
American and European/Eastern studies. In agree-
ment with previous observations,39,49 most cases have
an aggressive clinical behavior. In a few cases, the
course of the disease is indolent, with spontaneous
remission of skin lesions and long periods of stable
disease without associated systemic symptoms. Nei-
ther the age of the patients nor the aggressiveness of
the initial treatment was related to the course of the
disease. In agreement with previous observations,57 a
correlation was found between the expression of TCR-
//CD56 phenotype by tumor cells and an ag-
gressive course. Therefore, the presence of this pecu-
liar immunophenotypic profile may be indicative of a
dismal clinical course and may require aggressive
therapeutic modalities (CHOP-like or third generation
regimens, possibly followed by allogeneic bone mar-
row transplantation). Conversely, the finding of a
TCR-//CD56 phenotype may be indicative of an
indolent course and favor less aggressive treatments.
However, further studies are needed to confirm
whether the origin (/ or /) and CD56 expression
have a prognostic significance.
Increasing attention has been given to the clini-
copathologic spectrum of the CD56 lymphomas,
possibly due to the availability of a paraffin section-
reactive CD56 antibody, which has greatly facilitated
the recognition and further characterization of these
rare tumors.4 –5,63– 69 CD56 lymphomas show a poly-
morphous clinical presentation, a wide morphologic
spectrum, and a variable immunophenotypic profile.
For this reason, there is much confusion and little
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consensus regarding the best nomenclature for these
tumors. A review of the literature on this topic shows
that similar cases have been designated with different
terms, such as “aggressive natural killer cell leukemia/
lymphoma”,70,71 “large granular lymphocytic lympho-
ma”,72,73 “angiocentric T-cell lymphoma”,74 “CD56
T-”cell lymphoma,”75,76 “natural killer cell lymphoma”
and “CD56 angiocentric lymphoma”.78 A comprehen-
sive study provided a more complete picture of these
rare neoplasms and better clarified the clinicopatho-
logic spectrum of these uncommon tumors.5 In the
current study, we focused on NK and NK-like lympho-
mas with primary presentation of disease in the skin.
It should be noted that many of our cases had histo-
logic/immunophenotypic patterns that were difficult
to assign unambiguously to one or another of the
existing categories. In addition, this preliminary re-
view gave us reason to doubt that histopathologic
features by themselves were invariably specific. That
is, we frequently found it impossible to unequivocally
classify single cases on morphologic grounds alone.
The three cases of NK/T-cell lymphoma, nasal
type, showed the characteristic morphology (dermal
proliferation of small to medium pleomorphic cells,
with prominent angiocentricity and angiodestructive
growth as well as extensive necrosis), immunopheno-
type (CD3, CD3, CD56, CD45RO, TIA-1,
TCRs), and association with EBV, as previously de-
scribed.4,5,79 In addition, in the only patient with avail-
able follow-up information, the development of skin
lesions was rapidly followed by involvement of the
frontal paranasal sinuses and nasal cavity, in agree-
ment with the highly aggressive clinical behavior re-
ported in previous studies.4,5 An extensive immuno-
histochemical study on frozen section also showed an
NK CD2/CD94/NKp46 phenotype.
Clinically, in the group of CD4 NK cell lympho-
mas, a striking male preponderance was observed, in
agreement with previous observations.5,67 Histopatho-
logically, these cases showed a dermal infiltrate of
variably sized pleomorphic cells or monomorphic,
medium to large blasts. The neoplastic cells showed
an Indian file or reticular pattern of infiltration. The
angiocentric/angiodestructive features, although of-
ten observed, were never prominent as in the nasal
type NK/T-cell lymphoma. The immunophenotype
was CD3/, CD4, CD43, CD45RA/, CD56,
CD68/, CD123/IL3R, CD3, CD57, TCRs,
TIA-1, EBER and LMP-1, resembling the immu-
nophenotypic profile described by Petrella et al.6 as
“CD4, CD56 cutaneous lymphomas.” Possible ex-
amples were published by others.7,80,81 Therefore, we
preferred to retain this terminology instead of using
the one proposed by the WHO classification (blastic
NK-cell lymphoma).
The expression of CD4, CD56, CD68, and CD123
and the negativity of NKp46 and CD94 (in seven cases
tested), the striking male preponderance, and the sub-
sequent rapid spread to bone marrow, with or without
leukemic evolution, raise doubts concerning the ori-
gin/differentiation of tumor cells and the relationship
of this entity with other NK/T-cell lymphomas and
leukemias.4,5,70,82– 85 The CD4/CD68/CD123 phe-
notype was mainly expressed by immature monocytic
and dendritic cell precursors. The cases belonging to
this group, although primary cutaneous at presenta-
tion according to the EORTC definition2 and charac-
terized by initial response to the treatment with ag-
gressive polychemotherapy, experienced rapid spread
to the bone marrow, with or without leukemia, and
death notwithstanding aggressive second-line treat-
ments including bone marrow transplantation. We
recommend aggressive polychemotherapy possibly
followed by autologous or heterologous bone marrow
transplantation in patients presenting with dissemi-
nated cutaneous diseases and local radiotherapy and
close follow-up in patients who present with single,
isolated skin lesions.
The patient with blastoid NK cell lymphoma pre-
sented with the clinical symptoms (extranodal disease
at diagnosis, histopathologic features (monomor-
phous proliferation of medium to large cells in a reti-
form pattern reminiscent of leukemia), immunophe-
notypic profile (CD3, CD4, CD8, CD56, F1,
TCR1), the lack of association with EBV, and the
aggressive clinical course recently described by Chan
et al.5 as typical of this entity. For this reason, and
because of the lack of CD4 expression, we believe that
this case is phenotypically different from CD4NK-
like lymphoma. Therefore, we retained the original
terminology instead of using the one proposed by the
WHO classification, which lumps the two categories
under the heading “blastic NK cell lymphoma.” How-
ever, because few cases of blastoid NK cell lymphoma
have been reported, the proper nosology of these rare
cases and their relationship with other types of NK/T-
cell lymphomas/leukemias remain to be determined.
In particular, it cannot be excluded that both blastoid
NK cell lymphoma and CD4/CD56 primary cuta-
neous lymphoma partly overlap with or may be iden-
tical to the entity called blastic NK cell lymphoma
according to the WHO classification.1
The only case of intravascular, NK-like lymphoma
had such a distinctive morphoimmunophenotypic
profile that it deserves a separate category. We pre-
ferred to use NK-like instead of NK cell because we
were not able to investigate the TCR gene status. On
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histopathologic examination, our case exhibited the
typical intravascular accumulation of large atypical
cells, which dilated and occluded the vascular lumina
and were associated with fibrinous thrombi.86 To the
best of our knowledge, this is the first case reported of
an intravascular NK-like lymphoma. In fact, most of
the previously described cases showed a B-cell phe-
notype and a concurrent predilection for lung and
skin,87,88 whereas fewer reported cases of T-cell– de-
rived cases showed a clear-cut predilection for the
skin.88 –100 The current case characterized by complete
remission after initial aggressive polychemotherapy
(CHOP), metastasis to the CNS, and death 17 months
after diagnosis, has to be considered exceptional as
that putatively histiocytic variant reported.101
The group of cytotoxic, peripheral T-cell lympho-
mas by Snowden et al. represented a hodgepodge of
cases that did not have unifying features and were
lumped together because they did not conform to any
of the other categories. These cases were composed of
pleomorphic lymphocytes of variable size or blast-like
cells with the features of pleomorphic small to medi-
um-sized cutaneous T-cell lymphoma or large cell
cutaneous T-cell lymphoma, CD30, or large cell cu-
taneous T-cell lymphoma CD30/lymphomatoid
papulosis according to the EORTC classification. Al-
though the small number of cases does not us allow to
draw definite conclusions, it seems that the cytotoxic
phenotype does not significantly affect the clinical
evolution and prognosis of the single entities, similarly
to cytotoxic mycosis fungoides.
In conclusion, primary cutaneous lymphomas ex-
pressing the cytotoxic granule-associated protein
(TIA-1) and/or the NK cell marker (CD56) include
distinct groups of diseases, both clinically and biolog-
ically. Our objective was to clarify the clinical, mor-
phologic, and phenotypic features of these distinct
categories, which are often characterized by a highly
aggressive behavior. Because the finding of a cytotoxic
phenotype often has prognostic significance, the rou-
tine use of cytotoxic markers in the diagnosis and
classification of cutaneous lymphomas should be ex-
panded.
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